SynthesisBMC gastroenterology2026
The role of autoimmune gastritis in gastric cancer risk: a systematic review and meta-analysis.
Synthesis in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAutoimmune gastritis (AIG) is a chronic, progressive condition characterized by immune-mediated attack on gastric parietal cells, predominantly in the corpus and fundus of the stomach. This process leads to mucosal atrophy, which is a key precursor lesion in the established Correa cascade of gastric carcinogenesis. While AIG has long been considered a precursor to gastric cancer (GC), the exact magnitude of this risk and the independent role of AIG remain debated. The primary purpose of this systematic review and meta-analysis was to evaluate the precise relationship between AIG and the risk of gastric cancer.
methodsWe performed a comprehensive search of relevant databases and included studies that assessed GC risk in patients diagnosed with AIG. The data were synthesized using random-effects models to calculate pooled hazard ratios (HRs). Studies were stratified based on H. pylori infection status and histological confirmation of AIG. Risk of bias was evaluated using the Cochrane risk-of-bias tool.
resultsThe meta-analysis included 8 studies with a total of 10 cohorts. The pooled HR for GC risk in patients with AIG was 1.93 (95% CI: 1.59–2.33). H. pylori-negative AIG patients exhibited a significantly higher risk (HR = 4.31) compared to those with H. pylori-positive AIG (HR = 2.36). Histologically confirmed AIG was associated with an increased risk of GC, with a pooled HR of 4.82 (95% CI: 2.44–9.51). Subgroup analysis of studies diagnosing AIG histologically showed no heterogeneity (I² = 0%). The overall heterogeneity across all studies was substantial, with an I² of 77%.
conclusionOur findings suggest that AIG may be a potential independent risk factor for GC particularly in H. pylori-negative patients and those with histologically confirmed AIG. These results highlight the importance of considering histological diagnosis and H. pylori status in clinical surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.